HomeHealthcare & Life SciencesPharmaceuticals Myasthenia Gravis Treatment Market

France Myasthenia Gravis Treatment Market Size & Outlook, 2025-2033


France Myasthenia Gravis Treatment Market Insights

  • Reed Intelligence analysis indicates that the France Myasthenia Gravis Treatment Market size, valued at USD 88.77 Million in 2024, is expected to expand to USD 200.97 Million by 2033.
  • The France market is forecasted to expand at a CAGR of 9.52% spanning 2026–2033.
  • Ocular MG  held the leading position among By Type segments in 2024, based on market size.
  • Congenital MG  is projected to post the fastest growth rate, sustaining its position as the most attractive By Type segment during the forecast horizon.

Other Key Findings


  • As of 2024, France held 4.21% of the global Myasthenia Gravis Treatment Market size.
  • By 2033, United States is anticipated to capture the largest share of the global Myasthenia Gravis Treatment Market.
  • In Europe, Germany is expected to lead the regional Myasthenia Gravis Treatment Market size by 2033.
  • Benelux will remain the fastest-growing market in Europe, reaching USD 97.67 Million by 2033.

Report Summary

Report Scope Details
Base Year for Study 2024
Study Period 2021-2033
Historical Period 2021-2023
Forecast Period 2025-2033
Market Size In 2024 USD 88.77 Million
Market Size In 2033 USD 200.97 Million
Largest segment Ocular MG 
Units Revenue in USD Million
CAGR 9.52% (2025-2033)
Segmnetation Covered
By Type
  1. Ocular MG 
  2. Congenital MG 
  3. Transient Neonatal MG
By Treatment
  1. Medication 
  2. Surgery 
  3. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
  4. Plasmapheresis and Intravenous Immunoglobulin 
  5. Others
By End-User
  1. Hospitals 
  2. Clinics 
  3. Academic Research Institutes 
  4. Others
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Related Reports